PROC and Sepsis: In the clinical trial lead by the Recombinant Human Activated Protein C Woldwide Evaluation in Severe Sepsis (PROWESS) Study group, recombinant human activated protein C (rhAPC) was shown to reduce patient mortality from sepsis (46).